JP2019507183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019507183A5 JP2019507183A5 JP2018559164A JP2018559164A JP2019507183A5 JP 2019507183 A5 JP2019507183 A5 JP 2019507183A5 JP 2018559164 A JP2018559164 A JP 2018559164A JP 2018559164 A JP2018559164 A JP 2018559164A JP 2019507183 A5 JP2019507183 A5 JP 2019507183A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- variable domain
- amino acid
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 230000001363 autoimmune Effects 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 208000027866 inflammatory disease Diseases 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 6
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 241000699802 Cricetulus griseus Species 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 206010024305 Leukaemia monocytic Diseases 0.000 claims description 2
- 206010028116 Mucosal inflammation Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 208000010399 Wasting Syndrome Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 201000006894 monocytic leukemia Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 210000003757 neuroblast Anatomy 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021047470A JP7140867B2 (ja) | 2016-01-29 | 2021-03-22 | Ｐｄ－ｌ１に結合する抗原結合性タンパク質 |
| JP2022067548A JP2022095910A (ja) | 2016-01-29 | 2022-04-15 | Ｐｄ－ｌ１に結合する抗原結合性タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662288912P | 2016-01-29 | 2016-01-29 | |
| US62/288,912 | 2016-01-29 | ||
| PCT/US2017/015429 WO2017132562A1 (en) | 2016-01-29 | 2017-01-27 | Antigen binding proteins that bind pd-l1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021047470A Division JP7140867B2 (ja) | 2016-01-29 | 2021-03-22 | Ｐｄ－ｌ１に結合する抗原結合性タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019507183A JP2019507183A (ja) | 2019-03-14 |
| JP2019507183A5 true JP2019507183A5 (enExample) | 2019-12-26 |
| JP6883590B2 JP6883590B2 (ja) | 2021-06-09 |
Family
ID=59386438
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559164A Active JP6883590B2 (ja) | 2016-01-29 | 2017-01-27 | Ｐｄ−ｌ１に結合する抗原結合性タンパク質 |
| JP2021047470A Active JP7140867B2 (ja) | 2016-01-29 | 2021-03-22 | Ｐｄ－ｌ１に結合する抗原結合性タンパク質 |
| JP2022067548A Pending JP2022095910A (ja) | 2016-01-29 | 2022-04-15 | Ｐｄ－ｌ１に結合する抗原結合性タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021047470A Active JP7140867B2 (ja) | 2016-01-29 | 2021-03-22 | Ｐｄ－ｌ１に結合する抗原結合性タンパク質 |
| JP2022067548A Pending JP2022095910A (ja) | 2016-01-29 | 2022-04-15 | Ｐｄ－ｌ１に結合する抗原結合性タンパク質 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10118963B2 (enExample) |
| EP (1) | EP3408400B1 (enExample) |
| JP (3) | JP6883590B2 (enExample) |
| KR (1) | KR20190026642A (enExample) |
| CN (2) | CN109715821B (enExample) |
| AU (1) | AU2017212717B2 (enExample) |
| BR (1) | BR112018015480A2 (enExample) |
| CA (1) | CA3013051A1 (enExample) |
| CL (1) | CL2018002034A1 (enExample) |
| EA (1) | EA037855B1 (enExample) |
| ES (1) | ES2986360T3 (enExample) |
| IL (1) | IL260846B2 (enExample) |
| MX (2) | MX2018009228A (enExample) |
| NZ (1) | NZ745357A (enExample) |
| PH (1) | PH12018501611A1 (enExample) |
| SG (1) | SG11201806496SA (enExample) |
| TW (1) | TWI760323B (enExample) |
| WO (1) | WO2017132562A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| BR112018015480A2 (pt) * | 2016-01-29 | 2019-05-21 | Sorrento Therapeutics, Inc. | proteínas de ligação ao antígeno que se ligam a pd-l1 |
| WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| EP3768713A2 (en) | 2018-03-22 | 2021-01-27 | Keires AG | Antagonistic pd-1, pd-l1 and lag-3 binding proteins |
| US11993655B2 (en) | 2018-04-09 | 2024-05-28 | Oricell Therapeutics Co., Ltd. | Anti-PD-L1 antibody and use thereof |
| WO2019228514A1 (en) | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and uses thereof for treating disease or condition |
| WO2019227490A1 (en) * | 2018-06-01 | 2019-12-05 | Tayu Huaxia Biotech Medical Group Co., Ltd. | Compositions and methods for imaging |
| SG11202101757QA (en) * | 2018-08-20 | 2021-03-30 | 1Globe Biomedical Co Ltd | Novel cancer immunotherapy antibody compositions |
| US20220177561A1 (en) * | 2018-12-11 | 2022-06-09 | Sanford Burnham Prebys Medical Discovery Institute | Models and Methods Useful for the Treatment of Serrated Colorectal Cancer |
| CN113795511B (zh) | 2019-01-23 | 2024-07-23 | 大有华夏生物医药集团有限公司 | 抗pd-l1双抗体及其用途 |
| JP7725066B2 (ja) | 2019-04-18 | 2025-08-19 | キューエルエスエフ バイオセラピューティック インコーポレイテッド | ヒト化抗ｐｄ－ｌ１抗体 |
| BR112021016512A2 (pt) | 2019-08-29 | 2022-03-15 | Remegen Co Ltd | Anticorpo anti pd-l1 e uso do mesmo |
| WO2021263169A2 (en) * | 2020-06-26 | 2021-12-30 | Sorrento Therapeutics, Inc. | Oncolytic viruses expressing immunomodulatory fusion proteins |
| WO2022051414A1 (en) | 2020-09-02 | 2022-03-10 | Mayo Foundation For Medical Education And Research | Antibody-nanoparticle complexes and methods for making and using the same |
| KR102557472B1 (ko) | 2020-11-16 | 2023-07-21 | 주식회사 이뮨온시아 | 면역항암제에 대한 치료 반응성을 예측하기 위한 바이오마커 및 이의 용도 |
| EP4335872A4 (en) * | 2021-05-07 | 2025-10-29 | Immuneoncia Therapeutics Inc | BI-SPECIFIC ANTIBODY BINDING SPECIFICALLY TO CD47 AND PD-L1 |
| AU2022290563A1 (en) | 2021-06-09 | 2024-01-25 | Sofusa Holdings Llc | Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device |
| CA3267341A1 (en) * | 2022-09-19 | 2024-03-28 | Sonoma Biotherapeutics, Inc. | Specific chimeric antigen receptors for a citrullinated antigen to target regulatory T lymphocytes for the treatment of hidradenitis suppurativa |
| EP4658310A1 (en) | 2023-01-30 | 2025-12-10 | Kymab Limited | Antibodies |
| KR20250133603A (ko) * | 2024-02-29 | 2025-09-08 | 주식회사유한양행 | 항-tigit/항-pd-l1 이중특이적 항체 및 이의 용도 |
| CN121175334A (zh) | 2024-04-13 | 2025-12-19 | 益免安协公司 | 在治疗癌症中的使用pd-l1抑制剂的新辅助免疫疗法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
| JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用 |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| NZ255041A (en) | 1992-07-13 | 1996-11-26 | Bionebraska Inc | Preparation of a recombinant single copy polypeptide or portion thereof modified with a terminal alpha amino carbon reactive group and reactive side chain groups involving biologically added protective groups |
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| EP0672141B1 (en) | 1992-10-23 | 2003-05-14 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| AU770555B2 (en) | 1998-08-17 | 2004-02-26 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| US6938003B2 (en) | 2000-06-30 | 2005-08-30 | Mahesh Harpale | Method and apparatus for a credibility reporting system to augment an online exchange |
| ES2367891T3 (es) | 2000-09-29 | 2011-11-10 | Schering Corporation | Interleucina-10 pegilada. |
| GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| US8222214B2 (en) | 2007-06-01 | 2012-07-17 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Vaccine for the prevention of breast cancer relapse |
| US8877688B2 (en) * | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US9175082B2 (en) * | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| CN107892719B (zh) * | 2012-10-04 | 2022-01-14 | 达纳－法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
| AR093984A1 (es) * | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| CN111423511B (zh) * | 2013-05-31 | 2024-02-23 | 索伦托药业有限公司 | 与pd-1结合的抗原结合蛋白 |
| ES2861600T3 (es) * | 2014-04-04 | 2021-10-06 | Mayo Found Medical Education & Res | Isotipaje de inmunoglobulinas usando masa molecular precisa |
| CN105238762A (zh) * | 2015-10-26 | 2016-01-13 | 无锡傲锐东源生物科技有限公司 | 抗pd-1蛋白单克隆抗体杂交瘤细胞及其产生的抗pd-1单克隆抗体和应用 |
| BR112018015480A2 (pt) * | 2016-01-29 | 2019-05-21 | Sorrento Therapeutics, Inc. | proteínas de ligação ao antígeno que se ligam a pd-l1 |
-
2017
- 2017-01-27 BR BR112018015480-6A patent/BR112018015480A2/pt not_active Application Discontinuation
- 2017-01-27 CN CN201780021396.XA patent/CN109715821B/zh active Active
- 2017-01-27 ES ES17745008T patent/ES2986360T3/es active Active
- 2017-01-27 EA EA201891709A patent/EA037855B1/ru unknown
- 2017-01-27 US US15/418,514 patent/US10118963B2/en active Active
- 2017-01-27 CA CA3013051A patent/CA3013051A1/en active Pending
- 2017-01-27 MX MX2018009228A patent/MX2018009228A/es unknown
- 2017-01-27 CN CN202210999239.9A patent/CN116333124A/zh active Pending
- 2017-01-27 KR KR1020187024978A patent/KR20190026642A/ko active Pending
- 2017-01-27 JP JP2018559164A patent/JP6883590B2/ja active Active
- 2017-01-27 NZ NZ745357A patent/NZ745357A/en unknown
- 2017-01-27 AU AU2017212717A patent/AU2017212717B2/en active Active
- 2017-01-27 EP EP17745008.7A patent/EP3408400B1/en active Active
- 2017-01-27 WO PCT/US2017/015429 patent/WO2017132562A1/en not_active Ceased
- 2017-01-27 SG SG11201806496SA patent/SG11201806496SA/en unknown
- 2017-02-02 TW TW106103519A patent/TWI760323B/zh active
-
2018
- 2018-07-27 MX MX2022011659A patent/MX2022011659A/es unknown
- 2018-07-27 CL CL2018002034A patent/CL2018002034A1/es unknown
- 2018-07-29 IL IL260846A patent/IL260846B2/en unknown
- 2018-07-30 PH PH12018501611A patent/PH12018501611A1/en unknown
- 2018-10-10 US US16/156,895 patent/US10919964B2/en active Active
-
2021
- 2021-01-13 US US17/148,450 patent/US11919952B2/en active Active
- 2021-03-22 JP JP2021047470A patent/JP7140867B2/ja active Active
-
2022
- 2022-04-15 JP JP2022067548A patent/JP2022095910A/ja active Pending
-
2024
- 2024-01-12 US US18/412,102 patent/US20240190959A1/en active Pending